{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T11:11:31Z","timestamp":1694776291842},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Few studies have addressed the impact of adefovir dipivoxil (ADV)-based combination therapy on the renal function of patients with chronic hepatitis B (CHB). This study evaluated the effects of ADV combined with other antiviral nucleotide analogs (NAs) on renal function of patients with CHB, and analyzed the risk factors for more than 20% reduction of baseline estimated glomerular filtration rate (eGFR).<\/jats:p>\n            <jats:p>The data of 164 patients with CHB were retrospectively analyzed in this study. Of the 164 patients, 42 received entecavir (ETV) combined with ADV (ETV\u200a+\u200aADV group), 68 lamivudine (LAM) combined with ADV (LAM\u200a+\u200aADV group), and 54 telbivudine (LDT) combined with ADV (LDT\u200a+\u200aADV group). Serum creatinine (SCr) level, eGFR, and proportion of patients with eGFR \u2265 90 mL\/min\/1.73 m<jats:sup>2<\/jats:sup> were observed. Also, the independent risk factors for more than 20% reduction of baseline eGFR were analyzed.<\/jats:p>\n            <jats:p>After 104-week combination therapy, compared with the baseline level, SCr levels were significantly increased in the ETV\u200a+\u200aADV group (67\u200a\u03bcmol\/L vs 73\u200a\u03bcmol\/L, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.012) and LAM\u200a+\u200aADV group (68\u200a\u03bcmol\/L vs 79\u200a\u03bcmol\/L, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.008), but it was significantly decreased in the LDT\u200a+\u200aADV group (69\u200a\u03bcmol\/L vs 64\u200a\u03bcmol\/L, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.023). Compared with the baseline level, eGFR was significantly decreased in the ETV\u200a+\u200aADV group (107.8 mL\/min\/1.73 m<jats:sup>2<\/jats:sup> vs 96.1\u200amL\/min 1.73\/m<jats:sup>2<\/jats:sup>, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.004), and LAM\u200a+\u200aADV group (105.4 mL\/min\/1.73 m<jats:sup>2<\/jats:sup> vs 87.3 mL\/min\/1.73 m<jats:sup>2<\/jats:sup>\n                                 <jats:italic toggle=\"yes\">, P<\/jats:italic>\u200a=\u200a.000), but it was significantly increased in the LDT\u200a+\u200aADV group (104.1\u200amL\/min 1.73\/m<jats:sup>2<\/jats:sup> vs 116.2 mL\/min\/1.73 m<jats:sup>2<\/jats:sup>\n                                 <jats:sub>,<\/jats:sub>\n                                 <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.005). The proportion of patients with normal renal function (\u226590 mL\/min\/1.73 m<jats:sup>2<\/jats:sup>) was significantly higher in the LDT\u200a+\u200aADV group than in the ETV\u200a+\u200aADV group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.002) and LAM\u200a+\u200aADV group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.001). Multivariate analysis showed that age (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.035), male (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.005), baseline eGFR (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001), LAM combined with ADV (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.008), and ETV combined with ADV (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.03) were independent risk factors for 20% reduction of baseline eGFR.<\/jats:p>\n            <jats:p>As compared with ETV and ADV combination therapy as well as LAM and ADV combination therapy, LDT and ADV combination therapy can improve eGFR level, so LDT and ADV combination therapy is suitable for the patients with potential renal impairment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000013430","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T11:39:52Z","timestamp":1543491592000},"page":"e13430","source":"Crossref","is-referenced-by-count":1,"title":["Telbivudine and adefovir dipivoxil combination therapy improves renal function in patients with chronic hepatitis B"],"prefix":"10.1097","volume":"97","author":[{"given":"Yong","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Infection Disease, Tongcheng County People's Hospital, Xianning"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-wang","family":"Nie","sequence":"additional","affiliation":[{"name":"Department of Infection Disease, The Second Hospital of Dalian Medical University, Dalian, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1872-034X.2009.00633.x","article-title":"Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan","volume":"40","author":"Kumada","year":"2010","journal-title":"Hepatol Res"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"EASL Clinical Practice Guidelines: management of chronic hepatitis, B, virus, infection","volume":"57","year":"2012","journal-title":"Hepatology"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3851\/IMP1474","article-title":"Liver transient elastography (Fibroscan): a place in the management algorithms of chronic viral hepatitis","volume":"15","author":"Scott","year":"2010","journal-title":"Antivir Ther"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1053\/j.gastro.2006.09.020","article-title":"Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years","volume":"131","author":"Hadziyannis","year":"2006","journal-title":"Gastroenterology"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1111\/jvh.12025","article-title":"Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B","volume":"20","author":"Wang","year":"2013","journal-title":"J Viral Hepat"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa033364","article-title":"Lamivudine for patients with chronic hepatitis B and advanced liver disease","volume":"351","author":"Liaw","year":"2004","journal-title":"N Engl J Med"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/jmv.22227","article-title":"Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B","volume":"84","author":"Kim","year":"2012","journal-title":"J Med Virol"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/hep.25735","article-title":"Association of AKI with mortality and complications in hospitalized patients with cirrhosis","volume":"57","author":"Belcher","year":"2013","journal-title":"Hepatology"},{"key":"R9-20230914","first-page":"1","article-title":"The guideline of prevention and treatment for chronic hepatitis B","volume":"27","year":"2011","journal-title":"Clin Hepatol"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/sj.ki.5002729","article-title":"Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review","volume":"73","author":"Ceca","year":"2008","journal-title":"Kidney Int"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"139","author":"Levey","year":"2003","journal-title":"Ann Intern Med"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/jvh.12229","article-title":"Impact of nucleos (t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in China","volume":"22","author":"Qi","year":"2015","journal-title":"J Viral Hepat"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","article-title":"Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B","volume":"359","author":"Marcellin","year":"2008","journal-title":"N Engl J Med"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1128\/AAC.00350-08","article-title":"Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects","volume":"52","author":"Van Rompay","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa020681","article-title":"Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"348","author":"Marcellin","year":"2003","journal-title":"N Engl J Med"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/jvh.12217","article-title":"Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy","volume":"21","author":"Lee","year":"2014","journal-title":"J Viral Hepatitis"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1097\/MD.0000000000000646","article-title":"Impact of nucleos (t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B","volume":"94","author":"Qi","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1440-1746.2011.06852.x","article-title":"Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients","volume":"27","author":"Kim","year":"2012","journal-title":"J Gastroenterol Hepatol"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1128\/AAC.00914-09","article-title":"Mitochondrial DNA depletion and respiratory chain activity in primary human subcutaneous adipocytes treated with nucleoside analogue reverse transcriptase inhibitors","volume":"54","author":"Stankov","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"925","DOI":"10.5858\/2010-0356-RAR.1","article-title":"Mitochondnal disorders of DNA polymerase \u03b3 dysfunction: from anatomic to molecular pathology diagnosis","volume":"135","author":"Zhang","year":"2011","journal-title":"Arch Pathol Lab Med"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.2165\/11204330-000000000-00000","article-title":"Telbivudine: a review of its use in compensated chronic hepatitis B","volume":"70","author":"McKeage","year":"2010","journal-title":"Drugs"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1365-2893.2012.01600.x","article-title":"Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis","volume":"19","author":"Chan","year":"2012","journal-title":"J Viral Hepat"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201811300-00074","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T19:16:42Z","timestamp":1694719002000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201811300-00074"}},"subtitle":["A STROBE-compliant article"],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":22,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000013430","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]}}}